You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 12, 2025

Drugs in MeSH Category Adrenergic Agents


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Fl Inc AMPHETAMINE amphetamine TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 209253-006 Jun 22, 2023 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Rexar METHAMPHETAMINE HYDROCHLORIDE methamphetamine hydrochloride TABLET;ORAL 084931-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Neos Theraps ADZENYS XR-ODT amphetamine TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 204326-004 Jan 27, 2016 RX Yes No 9,839,619 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Adrenergic Agents Market Analysis and Financial Projection

The market for adrenergic agents is experiencing dynamic growth driven by therapeutic innovations and expanding applications, while the patent landscape reflects strategic R&D investments and evolving competitive pressures. Below is a detailed analysis of both domains:


Market Dynamics

Growth Drivers

  • Cardiovascular disease prevalence: Responsible for 17.9M global deaths annually, driving demand for β-blockers like metoprolol and carvedilol[2].
  • Aging populations: 76% of seniors have ≥2 chronic conditions, increasing usage of adrenergic drugs for hypertension and mental health disorders[2].
  • Expanding therapeutic applications: Emerging uses in anxiety, migraines, and cancer[3].

Market Size & Projections

  • Overall adrenergic drug market: Valued at $3.18B in 2024, expected to grow at 6.1% CAGR to $6.87B by 2037[2].
  • α2-adrenergic agonists: Projected to reach $2.35B by 2033, growing at 5.5% CAGR (from $1.45B in 2024)[7].

Regional Insights

  • North America: Holds 35% market share due to high chronic disease burden and pharmaceutical spending[2].
  • Asia-Pacific: Fastest growth, fueled by COPD prevalence (impacting 6.3% of the population) and rising cardiovascular awareness[2][3].

Key Trends

  1. Personalized medicine: Genetic profiling to optimize drug efficacy (e.g., Adial Pharmaceuticals’ AD04 for opioid/alcohol use disorder)[10].
  2. Innovative formulations: Extended-release β-blockers, transdermal patches, and stable liquid formulations (e.g., Novalar’s α-antagonist patent)[9].
  3. Cost-effectiveness focus: Payers increasingly demand pharmacoeconomic data for formulary inclusion[5].

Patent Landscape

Strategic Patent Holdings Patent No. Assignee Key Innovation Target Indication
8,247,415 Merck Sharp & Dohme Hydroxymethyl pyrrolidines as β3 agonists Metabolic disorders, obesity[1]
6,673,337 Allergan α2-agonist compositions with carboxymethylcellulose Glaucoma, anesthesia reversal[6]
6,730,792 Boehringer Ingelheim β3 agonists for lipolysis enhancement Obesity, type 2 diabetes[11]

Emerging Innovations

  • Biotech mergers: Consolidation (e.g., Allergan’s acquisition activity) to pool R&D resources[3].
  • Novel delivery systems: Inhalable β2-agonists for asthma/COPD and biodegradable implants (e.g., MedinCell’s BEPO® tech)[13].

Challenges

  • Generic competition: 1984 Hatch-Waxman Act accelerates generics post-patent expiry, reducing branded drug revenues by 80% within 1–2 years[5].
  • Regulatory pressures: Stricter safety protocols and off-label use reimbursement hurdles (e.g., Medicaid formulary delays)[5][14].

Regulatory and Economic Factors

  • Patent-term extensions: Up to 5 years granted under the Drug Price Competition Act to offset FDA approval delays[5].
  • Global IP disparities: India’s denial of Novartis’ Gleevec patent (2015) underscores regional challenges in protecting incremental innovations[14].

Key Takeaways

  1. Adrenergic agents remain pivotal in treating cardiovascular/metabolic diseases, with R&D pivoting to novel mechanisms (e.g., β3 agonists for obesity).
  2. Market expansion hinges on addressing geriatric needs and diversifying into neuropsychiatric indications.
  3. Patent strategies increasingly prioritize formulation innovations and combinatory therapies to delay generic erosion.

FAQs
Q1 Which adrenergic drug class dominates current sales?
A1 β-blockers (e.g., atenolol) and α2-agonists (e.g., clonidine) lead due to cardiovascular applications[2][7].

Q2 How does personalized medicine impact adrenergic drug development?
A2 Genetic markers (e.g., SLC6A4 variants) enable targeted therapies like AD04 for addiction[10].

Q3 What risks do manufacturers face in emerging markets?
A3 Price controls and compulsory licensing (e.g., India’s patent laws) limit profitability[14].

Q4 Are biologics influencing this market?
A4 Limited penetration, though long-acting injectables (e.g., RPV-LAI for HIV) signal future trends[13].

Q5 How are payers shaping R&D priorities?
A5 Demands for cost-benefit analyses and comparative effectiveness data are redirecting investments[5].

References

  1. https://www.drugpatentwatch.com/p/patent/8247415
  2. https://www.researchnester.com/reports/adrenergic-drug-market/2541
  3. https://www.einpresswire.com/article/664228199/adrenergic-drug-market-emerging-trends-and-growth-prospects-during-2023-2032
  4. https://www.lb7.uscourts.gov/documents/16c651.pdf
  5. https://www.ncbi.nlm.nih.gov/books/NBK234316/
  6. https://www.drugpatentwatch.com/p/patent/6673337
  7. https://www.verifiedmarketreports.com/product/alpha-2-adrenergic-agonist-market/
  8. https://synapse.patsnap.com/blog/decoding-norepinephrine-bitartrate-a-comprehensive-study-of-its-randd-trends
  9. https://pubchem.ncbi.nlm.nih.gov/patent/US-7569230-B2
  10. https://www.psychiatrictimes.com/view/patent-issued-for-methods-of-identifying-patients-with-substance-use-associated-genetic-markers-treatment-with-ad04
  11. https://patents.google.com/patent/US6730792B2/en
  12. https://patents.google.com/patent/WO2003072572A1/en
  13. https://medicinespatentpool.org/uploads/2020/04/MPP-Unitaid_Intellectual-property-report-on-long-acting-technologies.pdf
  14. https://www.pharmacytimes.com/view/supp_2008-04_004
Last updated: 2025-03-23

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.